See All Slides - tctmd.com

Slides

Presentation Cell Therapy 2013

Regenerative Therapies After Acute Myocardial Infarction- Focus on Endpoints

Presenter: Stephen G. Ellis

January 22, 2013

Presentation Cell Therapy 2013

MPC's for Ischemic and Nonischemic Heart Failure

Presenter: Emerson C. Perin

January 22, 2013

Presentation Cell Therapy 2013

BMAC for CLI: Status of a Phase 3 Trial

Presenter: Amit Patel

January 22, 2013

Presentation Cell Therapy 2013

Swiss AMI Study: Long-term Findings

Presenter: Daniel S?rder

January 22, 2013

Presentation Cell Therapy 2013

CD-34+ Cells for Ischemic Heart Failure

Presenter: Bojan Vrtovec

January 22, 2013

Presentation Cell Therapy 2013

REVIVE: Retrograde Bone Marrow-Derived Cells for Dilated Cardiomyopathy

Presenter: Amit N. Patel

January 22, 2013

Presentation Cell Therapy 2013

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

Presenter: Eduardo Marb?n

January 22, 2013

Presentation Cell Therapy 2013

SDF-1 Plasmid for Treatment of Critical Limb Ischemia

Presenter: David Paul Slovut

January 22, 2013

Presentation Cell Therapy 2013

Adipose derived cells or chronic myocardial ischemia

Presenter: Francisco Fdez-Avil?s

January 22, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Presenter: Kenneth M. Borow

January 22, 2013

Advertisement

Slides

Regenerative Therapies After Acute Myocardial Infarction- Focus on Endpoints

MPC's for Ischemic and Nonischemic Heart Failure

BMAC for CLI: Status of a Phase 3 Trial

Swiss AMI Study: Long-term Findings

CD-34+ Cells for Ischemic Heart Failure

REVIVE: Retrograde Bone Marrow-Derived Cells for Dilated Cardiomyopathy

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

SDF-1 Plasmid for Treatment of Critical Limb Ischemia

Adipose derived cells or chronic myocardial ischemia

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content